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Abstract
Background: MicroRNAs (miRNAs) are small non-coding RNA molecules that function as posttranscriptional
regulators of gene expression. Measurements of miRNAs in cerebrospinal fluid (CSF) and blood have just started
gaining attention as a novel diagnostic tool for various neurological conditions. The purpose of this exploratory
investigation was to analyze the expression of miRNAs in CSF and blood of patients with Alzheimer’s disease (AD)
and other neurodegenerative disorders in order to identify potential miRNA biomarker candidates able to separate
AD from other types of dementia.
Methods: CSF was collected by lumbar puncture performed on 10 patients diagnosed with AD and 10 patients
diagnosed with either vascular dementia, frontotemporal dementia or dementia with Lewy bodies. Blood samples
were taken immediately after. Total RNA was extracted from cell free fractions of CSF and plasma, and a screening
for 372 known miRNA sequences was carried out by real time quantitative polymerase chain reactions (miRCURY
LNA™ Universal RT miRNA PCR, Polyadenylation and cDNA synthesis kit, Exiqon).
Results: Fifty-two miRNAs were detected in CSF in at least nine out of ten patients in both groups. Among these,
two miRNAs (let-7i-5p and miR-15a-5p) were found significantly up-regulated and one miRNA (miR-29c-3p) was
found significantly down-regulated in patients with AD compared to controls. One hundred and sixty-eight miRNAs
were frequently detected in the blood, among which miR-590-5p and miR-142-5p were significantly up-regulated
and miR-194-5p was significantly down-regulated in AD patients compared to controls.
Conclusions: Detection of miRNA expression profiles in blood and in particular CSF of patients diagnosed with different
types of dementia is feasible and it seems that several expressional differences between AD and other dementia types do
exist when measured in a clinically relevant setup. In this explorative pilot study, the deregulated miRNAs in CSF of AD
patients may be associated with relevant target genes related to AD pathology, including APP and BACE1, which
suggests that miRNAs are interesting candidates for AD biomarkers in the future.
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Background
Alzheimer’s disease (AD) is an age-related progressive
neurodegenerative disorder characterized by cognitive
impairment and neuropsychiatric symptoms leading to re-
strictions in the activities of daily living. AD is the most
common type of dementia accounting for 50–70 % of
all dementia cases. Approximately 10 % of elderly people
(65+ years) are affected by AD with an age-specific preva-
lence that almost doubles every five years after 65 [1].
Because of the ageing population worldwide, the increas-
ing incidence and socioeconomic impact of AD and other
dementias represents a growing challenge to public health
all over the world [2, 3].
The complex neurobiology of AD, which is not fully
understood, includes the development of extracellular
amyloid plaques and intracellular neurofibrillary tangles,
vascular changes, neuronal inflammation, neurochemical
changes, and progressive brain atrophy [4–7].
The prospect of getting an effective treatment is not
only complicated by the lack of knowledge about the
underlying pathophysiological mechanisms of AD but
also by the difficulty of accurately diagnosing AD at an
early stage.
When compared to healthy individuals, existing cere-
brospinal fluid (CSF) biomarkers support the clinical
diagnosis of AD with a high predictive accuracy, how-
ever, in differentiating AD from other types of dementia
(e.g. vascular dementia, frontotemporal dementia and
dementia with Lewy bodies) the current biomarkers have
their limitations. In a newly published meta-analysis the
sensitivity and specificity of CSF amyloid beta (Aβ1-42)
for separating AD from other dementias were estimated
to be 73 and 67 %, respectively [8]. For total CSF tau the
sensitivity has been estimated to be 70–75 % and the
specificity 74–90 % and for phospo-tau 79–88 % and
78–83 %, respectively, for separating AD from other
dementias [9].
Development of new and better biomarkers for AD
and other dementias would result in more accurate diag-
noses facilitating the possibility for an early and special-
ized treatment effort for the growing number of patients
with dementia. Especially now that medical treatment
options for AD are available, it is particularly important
to identify these patients at an early stage.
MicroRNAs (miRNAs) are small non-coding RNA mole-
cules of approximately 22 nucleotides in length that func-
tion as posttranscriptional regulators of gene expression. In
mammalian cells, miRNAs work through base pairing with
complementary sequences within messenger RNA (mRNA)
molecules, usually resulting in gene silencing via transla-
tional repression. Recent studies indicate that the expres-
sion patterns of miRNAs change in relation to various
neurological diseases including Alzheimer’s disease. Altered
expression of specific miRNAs in the brain of AD patients
compared to controls has been reported, including down-
regulation of miR-15a/b, mR-16, miR-29a/b, miR-195,
miR-103 and miR-107, which have all been shown to tar-
get the β-site amyloid precursor protein cleaving enzyme
1 (BACE1) involved in the formation of amyloid plaques
[10–15]. Lukiw et al. [16, 17] studied the miRNA expres-
sion in hippocampal tissue of AD patients, and found up-
regulation of specific pro-inflammatory miRNAs including
miR-9, miR-125b, miR-146a, and miR-155, which all seem
to be induced by NF-κB, thus indicating a possible role of
these miRNAs in neuronal inflammation in AD. On the
other hand, Cogswell et al. [18] have found a significant
down-regulation of miR-9 in the human hippocampus of
AD patients. miR-9 is known from several experimental
studies to regulate neuronal differentiation [19].
Measurements of miRNAs in biofluids such as CSF
and blood have just started to gain attention as a novel
diagnostic tool. Since CSF is separated from blood circu-
lation by the blood–brain barrier (BBB), it makes good
biological sense that the CSF could contain unique sig-
natures of miRNA expression specific for various CNS
pathologies. Therefore, miRNAs derived from CSF might
serve as more valid biomarkers for brain pathologies
than those of other body fluids.
To date only a few studies of miRNA expression in
CSF of AD patients have been published. In most of
them AD patients were compared to healthy controls, or
comparisons of AD patients categorized by different
Braak stages were done [18, 20–25]. Even less is known
about the differences in CSF miRNA levels between AD
and other types of dementia.
Bekris et al. [13] investigated miRNA expression by
qPCR in patients with AD compared to both healthy
controls and patients with other neurodegenerative dis-
eases. They found miR-15a elevated in the hippocampus
and plasma of AD patients where the level was positively
correlated with plaque scores. In CSF no expression dif-
ferences were identified. Burgos et al. [26] profiled miR-
NAs in CSF and serum by Next Generation Sequencing
from patients with AD, Parkinson’s disease (PD) and
neurologically healthy controls. Numerous deregulated
miRNAs between AD and controls in both CSF and
serum were found, whereas only a handful of miRNAs
was deregulated between patients with AD and PD. In
this study, the expression of several miRNAs in CSF was
correlated with Braak stages and tangle scores, including
miR-9-3p, for which the level decreased with disease
progression. Galimberti et al. [27] profiled miRNAs by
qPCR in serum and CSF of AD patients compared to
inflammatory and non-inflammatory neurological con-
trols as well as patients with frontotemporal dementia
(FTD). They reported down-regulation of miR-125b and
miR-26b in CSF of AD patients compared to non-
inflammatory controls.
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The limited number of studies comparing miRNA CSF
levels in AD patients versus patients with other types of
dementia and their opposing results justifies the need
for additional studies to investigate the utility of miR-
NAs as biomarkers in a clinical relevant setup.
The purpose of this exploratory investigation was to
analyze the expression of miRNAs by RT-qPCR in CSF
and blood from 10 patients diagnosed with Alzheimer’s
disease and 10 patients diagnosed with either vascular
dementia, frontotemporal dementia or dementia with Lewy
bodies in order to identify potential miRNA biomarker
candidates with the ability to separate AD from other types
of dementia using a clinically relevant setup.
Methods
Patient material and diagnostic evaluation
Patients who went through diagnostic evaluation at the
Memory Clinic, Department of Neurology, Nordsjæl-
lands Hospital, from May to December 2014, were asked
to participate. All patients gave written and oral in-
formed consent in accordance with the project approval
from the Danish Research Ethics Committee (project ID:
H-2-2013-069). After completed diagnostic evaluation
the study population consisted of 20 patients: one group
of AD patients (n = 10), and one control group of pa-
tients with other types of dementia, including vascular
dementia (n = 4), frontotemporal dementia (n = 4), and
dementia with Lewy bodies (n = 2).
Diagnoses were based on patient interviews with
supplemental reports from relatives/caregivers, physical
and neurological examination, evaluation of psychiatric
symptoms (if relevant), assessment of activities of daily
living, and cognitive testing by experienced specialist
neuropsychologists, whose test collection included Mini-
Mental State Examination (MMSE) and Addenbrooke’s
Cognitive Examination (ACE). In addition, all patients
went through paraclinical testing with standard blood
examinations, lumbar puncture and Computer Tomog-
raphy (CT) scan of the brain. If necessary, the CT scan
was supplemented by Magnetic Resonance Imaging (MRI)
of the brain to evaluate vascular abnormalities and/or
hippocampal atrophy. In addition, all patients underwent
functional imaging performed with Fluorodeoxyglucose
Positron Emission Tomography (18F-FDG-PET) to meas-
ure glucose metabolism in specific brain areas. Patients
with symptoms of dementia with Lewy bodies were
scanned with a Dopamine Active Transporter (DAT) scan
of the brain to verify low levels of dopamine in the basal
ganglia.
Lumbar punctures were done by sterile technique with
the use of a 0.7 mm spinal needle when the patients
attended their second visit at the clinic two weeks after
referral. At least 7 ml CSF were collected from each
patient. Blood samples were drawn immediately after the
lumbar puncture. CSF samples were analyzed for glu-
cose, protein, red and white blood cell count, oligoclonal
IgG bands, IgG index, total tau, phospo-tau and Aβ1-42
as well as CSF/serum albumin ratio using the routine
tests at the Department of Clinical Biochemistry. At the
same time 1 ml CSF and 1 ml blood from each patient
were collected in EDTA tubes for miRNA analysis.
Final diagnoses were made jointly by several specialist
neurologists based on all clinical evaluations and para-
clinical test results. For the clinical diagnosis of AD the
NINCDS-ADRDA criteria for research [28] were used.
Only patients who met the criteria for probable AD demen-
tia with evidence of the AD pathophysiological process
were included. All patients in the AD group were sporadic
AD patients with a mean age of 70 years. The diagnosis of
vascular dementia was made according to the NINDS-
AIREN criteria [29], and the clinical diagnoses of fronto-
temporal dementia and dementia with Lewy bodies were
made according to the McKhann criteria [30] and McKieth
criteria [31], respectively. Table 1 shows the demographic
data of the 20 included patients.
Samples for miRNA detection
For miRNA detection, CSF and blood from each patient
were centrifuged immediately after collection and the cell-
free fractions were stored at −80.0 °C. All further sample
preparations and experiments were conducted by Exiqon
A/S, Denmark. Total RNA was extracted from 200 μl CSF
and 200 μl plasma using spin column chromatography
(miRCURY™ RNA isolation kit for biofluids).
miRNA real-time qPCR
Ten microliters of RNA was reverse transcribed in 50-μl
reactions using the miRCURY LNA™ Universal RT miRNA
PCR, Polyadenylation and cDNA synthesis kit (Exiqon).
cDNA was diluted 50 times and assayed in 10-μl PCR
reactions. Each miRNA was assayed once by quantitative
polymerase chain reactions (qPCR) on the miRNA Ready-
to-Use PCR, Human panel I containing 372 specific
miRNA primers. Negative controls were performed and
profiled like the samples. Both RNA (Sp2, Sp4, Sp5, and
Sp6) and DNA (Sp3) spike-in controls were added to the
panel. Amplification was performed in a LightCycler® 480
Real-Time PCR System (Roche). Amplification curves were
analyzed using the Roche LC software, both for determin-
ation of Ct values and for melting curve analysis.
Data analysis and normalization
The amplification efficiency was calculated by using
LinReg software. All assays were inspected for distinct
temperature melting curves, which were checked to be
within known specifications for the assay. Only miRNAs
detected with Ct < 37 and, in addition, 3 Ct values less than
the negative control were included in the data analysis.
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Data that did not pass these criteria were omitted from
any further analysis. Thirty-two miRNAs were detected
in all CSF samples, and 115 miRNAs were detected in
all blood samples. Using NormFinder [32], the best
normalizer was found to be the average Ct value of
miRNAs detected in all samples of CSF and blood,
respectively, and these global means were used for
normalization (relative expression level = REL = 2-ΔCt)
[33]. Both RNA (Sp6) and DNA (Sp3) spike-in controls
showed steady levels across all samples indicating ac-
curate RT reaction and qPCR.
Statistics
The data of REL or log (REL) did not fit the normal
distribution. Therefore, a two-sided non-parametric
Mann–Whitney test was performed for statistical ana-
lyses (SPSS software) to compare medians (missing
values were excluded). P values less than 0.05 were
considered significant.
To analyze the predictive power of each miRNA with
respect to categorizing patients as having either AD or
another type of dementia, logistic regression analyses with
classification accuracies for each miRNA were performed.
For this purpose, a leave-one-out (LOO) cross-validation
procedure (R Statistics) was applied (missing values were
set to zero).
P values for categorical variables were calculated by
Fisher’s exact test, and p values for comparisons of age,
cognitive test score, and CSF routine markers were
calculated by student’s t-test.
Because of the high number of tests performed, all
P values were finally corrected for multiple testing
with the Benjamini-Hochberg procedure.
Results
miRNA distribution in body fluids
Overall, 312 miRNAs were detected in CSF or blood
in our study population. Of these, 227 miRNAs oc-
curred in both CSF and blood, 81 miRNAs occurred
in blood only, and a minor proportion of 4 miRNAs
was found exclusively in the CSF. Among the miR-
NAs detected in both CSF and blood, some miRNAs
were detected predominantly in the CSF and others
predominantly in the blood of all patients (Fig. 1)
Fig. 1 Distribution of the 312 miRNAs detected in CSF and blood of all patients. Blood > CSF: miRNAs detected more frequently in blood samples
than in CSF samples. CSF > blood: miRNAs detected more frequently in CSF samples than in blood samples. Blood = CSF: miRNAs detected with
equal frequency in blood and CSF samples
Table 1 Demographic data of the patients included
Variable Control group (range) AD group (range) Mean difference (CI) p
Number 10 10
Gender (female/male) 4/6 6/4 n.s.
Age (years) 69.4 (54–79) 70.0 (56–82) 0.6 (−8.7;9.8) n.s.
Duration (years) 2.8 (1.0-5.5) 2.3 (1.5-4.0) −0.5 (−1.9;0.9) n.s.
MMSE 24.1 21.4 −2,7 (−8.1;2.7) n.s.
ACE 75.4 67.3 −8.1 (−18.0;1.7) n.s.
Aβ1-42 [pg/ml CSF] 561.4 (315–865) 391.6 (242–755) −169.8 (−330.0;-9.6) 0.04
Total tau [pg/ml CSF] 481.4 (228–1200) 540.6 (371–742) 59.2 (−223.3;341.7) n.s.
P-tau [pg/ml CSF] 60.1 (31–148) 82.6 (55–110) 22.5 (−3.2;48.2) n.s.
Control group patients diagnosed with vascular dementia (n = 4), frontotemporal dementia (n = 4), and dementia with Lewy bodies (n = 2). AD group patients all
diagnosed with Alzheimer’s dementia. MMSE Mini-Mental State Examination score, ACE Addenbrooke’s Cognitive Examination score. Mean difference [CI] difference
of mean values between groups and 95 % confidence interval of the difference. p p-values of difference calculated by two-sided t-tests or Fisher’s exact test
(Gender), n.s. nonsignificant (p > 0.05)
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miRNAs in CSF
A total of 231 different miRNAs were detected in the
CSF. Only 32 different miRNAs were detected in all of
the 20 CSF samples. On average, 105 miRNAs were
detected in each patient, equally distributed among AD
patients and control patients with other types of demen-
tia. We found no significant difference in total amount
(Ct) and number of different miRNAs in the two groups.
Fifty-two miRNAs were detected in CSF in at least
nine out of ten patients in both groups. When compar-
ing these 52 miRNAs between AD patients and controls,
two miRNAs (let-7i-5p and miR-15a-5p) were found
significantly up-regulated and one miRNA (miR-29c-3p)
was found significantly down-regulated in patients with
AD (Table 2, Fig. 2). However, when adjusting all P values
with the Benjamini-Hochberg procedure for multiple test-
ing, none of them were statistically significant.
By combining two of the differentially expressed miR-
NAs (miR-29c-3p and miR-15a-5p) in a simple ratio
model (RELmiR-29c-3p/RELmiR-15a-5p) AD patients could
be separated from patients with other types of dementia
(cutoff value 0.92) with a sensitivity of 90 % and a speci-
ficity of 100 % (Fig. 2 part D). To analyze the predictive
power of each miRNA in order to categorize patients as
having either AD or another type of dementia logistic
regression analysis were done for the 52 frequently
detected miRNAs in CSF (Fig. 3). The best predictors
identified by this procedure were again miR-15a-5p and
miR-29c-3p with classification accuracies of 0.8 and 0.7,
respectively.
When considering the detected miRNAs in CSF as cat-
egorical variables, three miRNAs were found to be
expressed more often among AD patients compared to
controls (Table 3). This difference was most significant
for two miRNA in CSF (miR-199b-5p and miR-22-5p).
Both miRNAs were detected in the CSF of 50 % of AD
patients and were not detected in the CSF of controls.
miRNAs in blood
A total of 308 different miRNAs were detected in the
blood. Of these, 115 miRNAs were detected in all of the
20 blood samples. On average, 227 miRNAs were de-
tected in each patient. One hundred and sixty-eight
miRNAs were detected in at least nine out of 10 patients
in each group (Additional file 1). Among these, miR-
590-5p (fold change (FC) = 1.35, p = 0.002) and miR-142-
5p (FC = 1.22, p = 0.043) were significantly up-regulated
and miR-194-5p (FC = 0.54, p = 0.028) was significantly
down-regulated in AD patients compared to controls.
Again, these P values would not pass a Benjamini-
Hochberg correction for multiple testing.
When applying logistic regression analyses to blood
data we identified 30 miRNAs with classification accur-
acies above 0.50 (i.e. random guessing), of which miR-
590-5p and miR-194-5p had the highest accuracy values
(Additional file 2).
No candidates for categorical variables were identified
in the blood.
Blood–brain Barrier Function
As a measure of BBB dysfunction, the albumin CSF/
serum concentration quotient (Qalb) is a widely accepted
indicator [34]. Albumin is a serum protein that is nor-
mally prevented from passing into the CSF. However,
under certain conditions such as neuroinflammation the
BBB may become leaky allowing albumin molecules to
pass from the blood. In this study, four out of ten AD
patients had elevated Qalb values. Three patients in the
control group, one with vascular dementia and two with
frontotemporal dementia, also had elevated Qalb as sign
of a leaky BBB (Additional file 3).
Discussion
Cognitive impairment may occur in a wide range of
neurological, psychiatric and medical conditions, and the
differential diagnosis of AD may be difficult, particularly
against patients with other neurodegenerative or vascu-
lar brain diseases. Therefore we intended to set up a
clinical relevant study design by choosing a non-healthy
control group of patients with other types of dementia.
Thus, with this exploratory investigation we aimed to
identify expression differences of miRNAs in patients di-
agnosed with Alzheimer’s disease and patients diagnosed
with either vascular dementia, frontotemporal dementia
or dementia with Lewy bodies in order to identify poten-
tial miRNA biomarker candidates with the ability to sep-
arate AD from other types of dementia. By carrying out
a screening for 372 known miRNA sequences with RT-
qPCR we identified a differential expression pattern for
let-7i-5p, miR-15a-5p, and miR-29c-3p in the CSF of AD
patients and for miR-590-5p, miR-142-5p, and miR-194-
5p in the blood of AD patients as compared to patients
with other types of dementia.
Overall miRNA detection
On average, 105 different miRNAs were detected in the
CSF of both cases and controls. These findings are con-
sistent with results from other studies, including our
own previous study of miRNA detection in CSF of
stroke patients [35], in which a slightly smaller number
of miRNAs were identified (n = 73) in each patient. The
average number of detected miRNAs in blood was 227
as compared to 204 in our previous study, and the
distribution patterns of miRNAs in blood and CSF in
our studies have been very similar (Fig. 1) suggesting a
reliable miRNA analysis. Data have been thoroughly
checked using negative controls in the RT step and
melting curve analysis. Furthermore, the steady levels of
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Table 2 Regulation of the 52 most frequently detected miRNAs in CSF of patients with dementia
miRNA NAD Ncontrol MAD (range) Mcontrol (range) FC p
miR-15a-5p 10 10 1.20 (0.63–4.22) 0.83 (0.52–1.01) 1.44 0.005
miR-29c-3p 10 10 0.81 (0.47–1.55) 1.33 (0.75–1.78) 0.60 0.009
let-7i-5p 10 10 1.31 (0.67–3.23) 0.85 (0.27–1.27) 1.54 0.019
miR-22-3p 10 9 0.83 (0.20–1.75) 1.35 (0.83–2.01) 0.62 n.s.
miR-24-3p 9 10 0.91 (0.19–1.23) 1.17 (0.81–1.94) 0.78 n.s.
miR-185-5p 10 9 1.35 (0.39–5.13) 0.62 (0.30–1.45) 2.16 n.s.
miR-27b-3p 10 10 0.95 (0.49–1.48) 1.21 (0.63–1.87) 0.78 n.s.
miR-142-3p 9 9 1.19 (0.27–4.31) 0.86 (0.26–1.83) 1.38 n.s.
let-7 g-5p 10 10 1.09 (0.55–2.75) 0.79 (0.39–2.19) 1.37 n.s.
miR-23a-3p 10 10 0.92 (0.53–1.55) 1.11 (0.62–2.04) 0.82 n.s.
miR-23b-3p 10 10 1.00 (0.38–1.24) 1.05 (0.60–2.55) 0.94 n.s.
miR-130a-3p 10 10 0.82 (0.41–1.56) 1.22 (0.42–2.13) 0.67 n.s.
let-7c-5p 10 10 0.88 (0.37–2.21) 1.15 (0.35–3.09) 0.76 n.s.
miR-150-5p 10 9 0.89 (0.23–5.44) 0.82 (0.37–1.68) 1.09 n.s.
miR-361-5p 9 9 0.95 (0.47–1.32) 1.00 (0.70–1.51) 0.94 n.s.
miR-25-3p 10 9 1.00 (0.36–5.49) 0.87 (0.34–1.77) 1.14 n.s.
miR-221-3p 10 10 1.68 (0.15–3.04) 1.22 (0.15–1.70) 1.38 n.s.
miR-29a-3p 10 10 0.96 (0.72–1.30) 1.01 (0.71–1.71) 0.94 n.s.
miR-30a-5p 10 10 1.32 (0.20–2.91) 1.12 (0.37–1.91) 1.17 n.s.
miR-10b-5p 9 10 0.90 (0.26–5.08) 1.04 (0.21–1.70) 0.86 n.s.
let-7a-5p 10 10 0.80 (0.29–2.58) 1.14 (0.65–3.49) 0.70 n.s.
miR-125b-5p 10 10 0.85 (0.62–1.53) 0.98 (0.69–2.77) 0.87 n.s.
miR-16-5p 10 10 0.96 (0.05–9.45) 0.98 (0.56–1.47) 0.98 n.s.
miR-424-5p 10 10 1.19 (0.35–3.38) 0.72 (0.47–2.38) 1.65 n.s.
miR-143-3p 10 10 1.04 (0.45–1.48) 0.92 (0.69–2.32) 1.12 n.s.
miR-19a-3p 9 10 1.14 (0.21–3.68) 1.15 (0.65–1.49) 0.99 n.s.
miR-124-3p 10 9 1.31 (0.26–2.73) 1.21 (0.32–2.08) 1.08 n.s.
let-7b-5p 10 10 1.03 (0.31–3.50) 0.83 (0.45–3.39) 1.23 n.s.
miR-146a-5p 9 10 1.37 (0.23–2.40) 0.91 (0.20–2.69) 1.50 n.s.
let-7d-3p 9 10 1.02 (0.54–1.89) 1.33 (0.62–1.83) 0.76 n.s.
miR-125a-5p 10 9 1.21 (0.32–2.96) 0.71 (0.29–2.68) 1.69 n.s.
miR-27a-3p 9 10 1.14 (0.15–2.81) 1.29 (0.25–3.03) 0.88 n.s.
miR-30d-5p 10 10 1.16 (0.31–2.47) 1.15 (0.34–1.83) 1.01 n.s.
miR-99a-5p 10 10 0.98 (0.57–1.36) 1.07 (0.62–1.93) 0.91 n.s.
miR-145-5p 10 10 1.16 (0.30–1.73) 1.00 (0.47–2.05) 1.15 n.s.
miR-100-5p 10 10 0.92 (0.54–1.88) 1.07 (0.63–1.86) 0.85 n.s.
miR-223-3p 9 10 1.14 (0.86–2.74) 0.78 (0.22–4.81) 1.45 n.s.
miR-320a 10 10 0.94 (0.54–1.62) 1.05 (0.64–1.68) 0.90 n.s.
miR-497-5p 10 10 1.07 (0.51–1.72) 1.08 (0.64–1.81) 0.98 n.s.
miR-373-5p 9 10 1.10 (0.26–2.66) 1.11 (0.30–3.44) 0.98 n.s.
miR-204-5p 10 10 1.05 (0.07–2.30) 0.99 (0.47–2.28) 1.06 n.s.
miR-92a-3p 10 10 0.94 (0.70–3.69) 0.84 (0.47–2.17) 1.12 n.s.
miR-423-5p 10 10 1.11 (0.65–2.27) 0.78 (0.44–2.22) 1.42 n.s.
miR-19b-3p 10 10 1.08 (0.18–2.25) 1.20 (0.21–2.20) 0.90 n.s.
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DNA and RNA spike-ins indicate good technical perform-
ance of our profiling experiment.
Findings in CSF
In the CSF we identified a differential expression pattern
for miR-15a-5p, let-7i-5p, and miR-29c-3p. In our study,
miR-15a-5p was up-regulated with a fold change of 1.44
(p = 0.005) in the CSF of AD patients. Bekris et al. [13]
have previously found elevated levels of miR-15a in
plasma and hippocampal tissue of AD patients with a
positive correlation to plaque scores. By contrast, Hebert
et al. [15] have found miR-15a down-regulated in
cerebral cortex of AD patients compared to healthy
controls. Interestingly, miR-15a’s regulation of both APP
and BACE1 has been validated in various ways, includ-
ing reporter assay analysis [15, 36]. Since the miRNA-
mRNA binding usually results in gene silencing via
translational repression, one could argue that the level
of miR-15a-5p was expected to be lower in AD patients
compared to other types of dementia. However, as the
complex pathogenesis of late-onset AD is not limited to
an increased Aβ production but also involves impaired
Aβ clearance [37], the possible ways for interaction of
miR-15a-5p in AD biology are many. Among the list of
Table 2 Regulation of the 52 most frequently detected miRNAs in CSF of patients with dementia (Continued)
miR-9-5p 9 10 1.25 (0.50–1.97) 1.24 (0.24–3.11) 1.00 n.s.
miR-30c-5p 10 10 1.15 (0.20–2.57) 0.99 (0.37–2.38) 1.15 n.s.
miR-21-5p 10 10 0.89 (0.66–2.29) 1.06 (0.27–1.86) 0.83 n.s.
miR-34a-5p 10 9 0.99 (0.26–2.39) 1.06 (0.46–2.07) 0.94 n.s.
miR-101-3p 10 9 1.11 (0.37–1.48) 0.93 (0.56–2.64) 1.19 n.s.
miR-29b-3p 9 9 1.12 (0.31–1.76) 0.92 (0.49–2.02) 1.22 n.s.
miR-199a-3p 10 10 0.92 (0.58–3.40) 1.16 (0.39–1.67) 0.79 n.s.
miR-9-3p 10 10 1.13 (0.23–2.35) 1.02 (0.28–2.86) 1.09 n.s.
NAD number of Alzheimer patients in which the miRNA was detected, Ncontrol number of control patients in which the miRNA was detected, MAD the median of
relative expression levels among Alzheimer patients, Mcontrol median of relative expression levels among control patients, FC fold change of median values,
p p-values of difference calculated by two-sided nonparametric Mann–Whitney test (not corrected for multiple testing), n.s. nonsignificant (p > 0.05)
Fig. 2 Deregulated miRNAs in CSF of patients with Alzheimer’s disease (n = 10) compared to patients with other types of dementia (n = 10).
Aligned scatter plots show relative expression levels (REL) of let-7i-5p a, miR-15a-5p b, and miR-29c-3p c. Black bars indicate median values. In
part d the ratio RELmiR-29c-3p/RELmiR-15a-5p is calculated for each patient and plotted in an aligned scatter plot. The red dotted line indicates a
cutoff value of 0.92 where AD patients can be separated from control patients with a sensitivity of 90 % and a specificity of 100 %
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predicted targets for miR-15a obtained from the miR-
Walk database [38] we discovered other genes relevant
to late-onset AD [39] including CD2-associated protein
(CD2AP) which recently has been suggested to mediate
the integrity of the BBB [40].
In the CSF of AD patients we also found an up-
regulation of let-7i-5p (FC = 1.54, p = 0.019) compared to
other types of dementia. Burgos et al. [26] reported a
positive correlation between the level of let-7i-3p in
serum of AD patients and their Braak stages. Even more
interesting, Lehmann et al. [20] found let-7b, another
member of the let-7 family of miRNAs, elevated in the
CSF of AD patients. Through reporter assay experiments
and by intrathecal injection of let-7b into the CSF of
wild-type mice Lehmann et al. showed that extracellular
let-7b activated the RNA-sensning Toll-like receptor 7
(TLR7) in both immune cells and neurons, and that this
activation resulted in neuronal cell death. From these
experiments the authors hypothesized that extracellular
miRNAs like let-7 can contribute to spread neuronal
damage from one brain region through activation of
extracellular TLR4. Also Let-7i-5p, which was elevated
in the CSF of AD patients in our study, has specifically
been validated to target TLR7 [41].
We found miR-29c-3p down-regulated in the CSF of
AD patients with a FC of 0.60 (p = 0.009). This finding is
in accordance with the results from Hebert et al. [15] as
previously mentioned, who found a significant down-
regulation of miR-29a and miR-29b (other members of
the miR-29 family) in temporal and cerebellar cortical
tissue from sporadic AD patients compared to healthy
controls. BACE1 was validated as a target of miR-29a/b
by reporter assays, and furthermore the inhibiting effect
of miR-29a/b on BACE1 activity was corroborated by
gain- and loss of function experiments using HEK293
cells. In mice brain tissue and cell cultures, the suppress-
ing effect of miR-29c-3p (down-regulated in our study)
on BACE1 has also been validated by Zong et al. [42] by
various methods. Most recently, Lei et al. [11] found
down-regulation of miR-29c in brain tissues from spor-
adic AD patients in whom the miR-29c level was nega-
tively correlated with BACE1 mRNA level. In contrast to
these experiments and to our results (Table 2), Kiko et
al. [25] have found significant up-regulation of miR-29a
and miR-29b in the CSF of AD patients compared to
healthy control subjects. In this context, it has, however,
not been clarified whether each member of the miR-29
family of miRNAs is expected to be regulated in the
same direction.
When considering the detected miRNAs in CSF as
categorical variables, three miRNAs were found to be
expressed more often in the CSF of AD patients com-
pared to controls (Table 3), namely miR-199b-5p, miR-
22-5p, and miR-206. Taking into account the small study
population and the large number of observations in our
Fig. 3 Logistic regression cross-validated classification accuracies based on a leave-one-out procedure (LOO). The 52 most frequently detected miRNAs
in CSF are ordered by decreasing magnitude of predictive power. Red color indicates predictors with classification accuracy above random guessing
Table 3 miRNAs detected more often in CSF samples of AD
patients compared to patients with other types of dementia
miRNA NAD Ncontrol OR Sensitivity Specificity p
miR-199b-5p 5/10 0/10 21 50 100 0.03*
miR-22-5p 5/10 0/10 21 50 100 0.03*
miR-206 6/10 1/10 13.5 60 90 0.06
NAD number of patients with Alzheimer’s disease in which the miRNA was
detected, Ncontrol number of patients with other types of dementia in which
the miRNA was detected, OR odds ratio, p p-value (Fischer’s exact test). Star
indicates statistically significance (p < 0.05)
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qPCR experiment, however we cannot exclude the possi-
bility of randomness in this observation. The expression
of miR-206 has been linked to the regulation of brain-
derived neurotrophic factor (BDNF), a regulator of synaptic
plasticity and memory, which is known to be deficient in
AD brains. Lee et al. [43] found up-regulation of miR-206
in human temporal cortex of AD patients and in transgenic
AD mice, and validated its repression of BDNF by northern
blotting and qPCR. Similarly, Tian et al. [44] reported an
up-regulation of miR-206 in hippocampal tissue, cerebro-
spinal fluid, and plasma of embryonic APP/PS1 transgenic
mice, and found that miR-206 depressed the expression of
BDNF.
To our knowledge, the possible functions miR-199b-5p
and miR-22-5p in relation to AD and other dementias are
unknown.
Findings in blood
Despite the large number of frequently detected miRNAs
in the blood (n = 168), only three miRNAs (miR-590-5p,
miR-142-5p, and miR-194-5p) were identified as being
differential expressed between AD patients and controls.
The expression of miR-590-5p, which was up-regulated
in the blood of AD patients in our study, has previously
been reported up-regulated in plasma of patients with
vulnerable coronary artery disease [45]. The antisense
string, miR-590-3p, has been investigated in an extensive
study involving 274 patients with frontotemporal demen-
tia, 287 patients with AD, and 344 non-demented age-
matched controls [46]. In this study the expression of miR-
590-3p was decreased in mononuclear cells in peripheral
blood of AD patients compared to non-demented control
subjects, and its target hnRNPA1, a protein involved in the
maturation of APP, was up-regulated. The study is not
directly comparable to our experiment mainly because of
the different cells and body fluids examined, and therefore
the meaning of the oppositely directed regulation of miR-
590 found in these two studies remains unclear.
With regard to miR-142-5p, which was up-regulated
in the blood of AD patients in our study, the only vali-
dated target is nuclear factor, erythroid 2-like 2 (NRF2).
This transcription factor regulates several genes that
encode proteins involved in responses to injury and
inflammation which includes the production of free radi-
cals [47]. Results from other clinical studies are in some
ways different from ours. Cogswell et al. [18] found miR-
142-5p down-regulated in the CSF of AD patients
compared to controls, and Kumar et al. [48] found the
antisense string, miR-142-3p, down-regulated in plasma
of AD patients compared to both MCI patients and
healthy controls.
In our study, miR-194-5p was down-regulated in the
blood of AD patients. We have no knowledge from pre-
vious studies or from literature searches about the role
and function of this miRNA in relation to AD or other
types of dementia.
Another miRNA, miR-107, which we found non-
significantly down-regulated in the blood of AD patients,
but which had a relatively high classification accuracy
(Additional file 2), has interestingly been reported down-
regulated in the blood of AD patients in two previous
studies [49, 50]. This miRNA is known to target BACE1,
and the level of miR-107 was previously found down-
regulated in AD brain tissue, suggesting a role for miR-
107 in the pathogenesis of AD [10].
In summary, most of the deregulated miRNAs that we
have identified in both CSF and blood can be linked to rele-
vant target molecules, although the overall picture of our
findings is still unclear and warrants further elucidation.
Existing studies differ in design and extraction methods
making it difficult to compare results and to gain a
complete overview of miRNAs affected by AD.
Best biomarker candidates
A biomarker measured in the blood is preferable to more
invasive alternatives. Blood samples from patients are
obtained easily at a low cost and at a low risk of adverse
effects. However, blood is a systemic fluid which compos-
ition may reflect processes in other tissues or organs be-
sides the brain. CSF, on the other hand, which is protected
by the blood–brain barrier, ought to be a reliable biomarker
source for neurodegenerative diseases in the central ner-
vous system. In our study, the results from miRNA expres-
sion analysis in the CSF seem more interesting compared
to blood data in various ways. Firstly, an equal number of
miRNAs were differentially expressed in blood and CSF
despite the four times larger number of frequently detected
miRNAs in the blood. Secondly, we find it interesting that
the three differential expressed miRNAs in CSF (miR-29c-
3p, miR15a-5p, and let-7i-5p) could all be related to AD
relevant targets like APP and BACE1.
miR-29c-3p and miR-15a-5p had the highest classifica-
tion accuracies separately, and by combing them in a
simple ratio model (RELmiR-29c-3p/RELmiR-15a-5p) AD pa-
tients could be separated from patients with other types
of dementia (cutoff value 0.92) with a sensitivity of 90 %
and a specificity of 100 %. This ratio model is of course
associated with statistical uncertainty due to our small
population size, and should therefore only be seen as a
proposal for the use of these markers in future studies,
which are highly needed. Logistic regression models
that combines more than one miRNA is another ap-
proach, but again in this small sized pilot study it is
impossible to select a single best model according to
the low stability proportion of each predictor and none
of our P values were strong enough to be considered
significant after correction for multiple testing.
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The impact of the BBB
Although the CSF is isolated from the rest of the circula-
tion by the blood–brain barrier, under certain condi-
tions, such as inflammation, the barrier can become
leaky allowing molecules to pass from the blood. To
measure the BBB function we calculated CSF/serum
albumin ratios (Qalb) in the 20 patients included. In this
study, four out of ten AD patients had elevated Qalb
values. Three patients in the control group also had
elevated Qalb values indicating a leaky BBB. Thus, in
those patients the presence of miRNAs in the CSF could
simply be a result of contamination from the systemic
circulation. When examining the expression of miR-22-
5p, miR-199b-5p and miR-206 (detected in the CSF with
a frequency of 50 % in the AD group and 0 % in the
control group) we found no association between the
expression of these miRNAs in the blood and CSF of
patients with an elevated Qalb, suggesting that their pres-
ence in CSF does not seem to be explained by a leak in
BBB. Also, we did not find an obvious association be-
tween the expression of other miRNAs in blood and
CSF, although a direct correlation analysis between the
levels in blood and CSF was prevented due to the small
size of our study population. Lastly we noticed that some
miRNAs which have been characterized as brain specific,
such as miR-124 and miR-9, were detected predominantly
in the CSF, further indicating that the expression of miR-
NAs in the two body fluids is individually regulated and
probably unaffected by small disturbances in the BBB
function. Findings by Bekris et al. [13] and Burgos et al.
[26] support this notion since they also did not find any
correlation between the expression of individual miRNAs
in CSF and blood in their studies. Neither of these two
studies included other specific measures to evaluate the
integrity of the BBB whereas we calculated the Qalb as a
measure of BBB dysfunction [34]. The findings taken
together should, however, be interpreted with caution and
further studies are warranted to clarify the origin of miR-
NAs in the CSF and their transport across the BBB.
Conclusions
Detection of miRNA expression profiles in blood and in
particular CSF of patients diagnosed with different types
of dementia is feasible and it seems that several expres-
sional differences between AD and other dementia types
do exist in a clinically relevant setup like the present. In
this explorative pilot study, the deregulated miRNAs in
CSF of AD patients compared to a relevant non-healthy
control group may be associated with target genes related
to AD pathology, including APP and BACE1, which sug-
gests that miRNAs are interesting candidates for AD
biomarkers in the future.
Clinical validation of our findings in a larger scale is ob-
viously needed. We are currently working on a validation
study with larger study groups that will enable subgroup
analyses between the different types of dementia and also
allow us to make stronger model assumptions based on
combinations of several miRNAs as diagnostic biomarkers
of the different types of dementia.
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